The present disclosure relates pharmaceutical formulations comprising hydralazine in the treatment of eye diseases and conditions with the formulations. The present disclosure also related to methods of preparing the pharmaceutical formulations.

The present disclosure relates pharmaceutical formulations comprising hydralazine in the treatment of eye diseases and conditions with the formulations. The present disclosure also related to methods of preparing the pharmaceutical formulations.

Immunomodulator formulations for use in the treatment of disease of the GI tract. The formulations comprise a hydroxylase inhibitor and/or an immunosuppressant. Exemplary formulations comprise hydralazine as a hydroxylase inhibitor and/or cyclosporin A as an immunosuppressant.

Immunomodulator formulations for use in the treatment of disease of the Gl tract. The formulations comprise a hydroxylase inhibitor and/or an immunosuppressant. Exemplary formulations comprise hydralazine as a hydroxylase inhibitor and/or cyclosporin A as an immunosuppressant.

The invention relates to a sustained release form of hydralazine for use in cancer therapy. Said sustained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof such that the inventive composition can be used in cancer therapy.

The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine such as hydralazine hydrochloride that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina ischaemic heart disease arterial hypertension and related disease conditions. Preferably the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable diffusion and/or osmotic-controlled release profi...

The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release...

PROBLEM TO BE SOLVED: To provide compositions and methods for protection in a patient suffering from an eye disease such as age-related macular degeneration, and to provide a method for administering the same.